Laura Smith
Acute Care · Germantown, TNNPI 1407502396
Payments from drug & device makers
Across 453 payments — averaging $23.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Boehringer Ingelheim$979
- Sanofi$790
- Harmony Biosciences LLC$630
- Regeneron Healthcare Solutions, Inc.$518
- plus $4K from 31 others
What the payments were for
- Consulting fees$1501%
- Food & beverage$10,35798%
- Education$510%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 67 | $1,948 |
| GSK | 93 | $1,542 |
| Boehringer Ingelheim | 45 | $979 |
| Sanofi | 35 | $790 |
| Harmony Biosciences LLC | 22 | $630 |
| Regeneron Healthcare Solutions, Inc. | 19 | $518 |
| Insmed, Inc. | 26 | $468 |
| Mylan Specialty L.p. | 20 | $407 |
| Jazz Pharmaceuticals Inc. | 8 | $326 |
| Pulmonx Corporation | 2 | $297 |
| Viatris Specialty LLC | 14 | $269 |
| Amgen | 12 | $206 |
| Bayer | 14 | $204 |
| United Therapeutics Corporation | 4 | $170 |
| Mallinckrodt Hospital Products Inc. | 7 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $151 |
| Genentech USA, Inc. | 8 | $143 |
| ZOLL Respicardia, Inc. | 2 | $141 |
| Atricure, Inc. | 1 | $122 |
| Idorsia Pharmaceuticals US Inc | 1 | $121 |
| Merck | 7 | $118 |
| La Jolla Pharmaceutical Company | 4 | $105 |
| Verona Pharma, Inc. | 6 | $105 |
| Grifols USA, LLC | 3 | $97 |
| Baxter Healthcare | 4 | $79 |
| Actelion Pharmaceuticals US, Inc. | 3 | $69 |
| Novartis | 2 | $54 |
| Gilead | 2 | $52 |
| Electromed, Inc. | 2 | $50 |
| Lilly USA, LLC | 3 | $44 |
| Inspire Medical Systems, Inc. | 2 | $42 |
| ANI Pharmaceuticals, Inc. | 1 | $33 |
| AbbVie | 2 | $32 |
| Shionogi Inc | 1 | $29 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Liquidia Technologies, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$468
- FASENRA$461
- BREZTRI$454
- CHARTIS CATHETER$297
- ZEPHYR DELIVERY CATHETER$297
- ZEPHYR ENDOBRONCHIAL VALVE$297
- PULMONX CHARTIS TABLET CONSOLE$297
- XYWAV$150
- XYREM$150
- TEZSPIRE$126
- SYNERGY ABLATION SYSTEM$122
- ATRICLIP LAA EXCLUSION SYSTEM$122
- QUVIVIQ$121
- remede System$121
- NUCALA$117
- SYMBICORT$107
How this compares
$10,558 in reported general payments places this provider in the 95th percentile of 738 acute care providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 343 | $270,454 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 14 | $221,979 |
| NucalaMepolizumab | 57 | $210,842 |
| Dupixent PenDupilumab | 28 | $104,480 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 122 | $97,508 |
| Spiriva RespimatTiotropium Bromide | 46 | $49,122 |
| XolairOmalizumab | 12 | $41,492 |
| Breo ElliptaFluticasone/Vilanterol | 64 | $30,438 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $25,866 |
| SymbicortBudesonide/Formoterol Fumarate | 72 | $22,147 |
| Spiriva HandihalerTiotropium Bromide | 40 | $21,669 |
| Incruse ElliptaUmeclidinium Bromide | 38 | $13,965 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 448 | $13,724 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $12,672 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 66 | $11,986 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,542 | $555,492560 claims |
| Insmed, Inc.Arikayce | $468 | $221,97914 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,948 | $119,655194 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $979 | $61,79465 claims |
| MerckDulera | $118 | $5,94217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 738 acute care providers in Tennessee.
Other acute care in Germantown
- Marisa AustinGermantown$10K
- Linda DiepGermantown$7K
- Haley HoyNashville$368K
- Anne AlexandrovMemphis$110K
- Stephen MillerKnoxville$108K
- Shannon GraceNashville$57K
- Timothy BallardKnoxville$47K
- Kelsey MartinNashville$42K
- Barbara BrownNashville$36K
- Michelle GoochChattanooga$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.